VTS208 / VelaVigo - LARVOL DELTA

VTS208: A first-in-class CD3/CLDN18.2/CDH17 Tri-specific T cell engager (TCE) for the treatment of gastrointestinal (GI) cancer (AACR 2026) - "Zolbetuximab (Astellas' anti-CLDN18.2 mAb, approved) has validated CLDN18.2 as a promising tumor-associated antigen (TAA) for gastrointestinal (GI) cancer therapy. CLDN18.2-targeting T cell engagers (TCEs), including IBI389 (phase I) and ASP2138 (phase I), demonstrate anti-tumor activity in patients with low CLDN18.2 expression, indicating that the TCE modality is effective even with minimal TAA expression...Current development includes CMC process optimization and dose-range-finding (DRF) toxicity studies. With mini-pool fermentation titers of 4-6 g/L supporting targeted drug substance concentrations for subcutaneous administration, the IND application is scheduled for filing in H2 2026.In summary, VTS208's unique trispecific design and differentiated features demonstrate promising efficacy and safety, positioning it as a compelling first-in-class TCE candidate for clinical development."

Trispecific • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CDH17 • CLDN18